RAPP
Rapport TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
RAP-219 has already produced statistically significant Phase 2a proof-of-concept efficacy and tolerability data, management says FDA feedback supported advancement into two parallel Phase 3 trials, and the balance sheet plus Tenacia partnership provide time and some non-dilutive validation to pursue the program [#10-K-2026-03-10].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.9.
What can break
Cash burn accelerates as late-stage studies ramp, reviving dilution risk despite stated runway into 2H29.
Momentum
84
Value
42
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $52.00 · Bear $24.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $51.22
Why
Momentum84 · Δ7d -4.9
Value42 · Δ7d +0.1
Sentiment56 · Δ7d +4.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.9
Δ21d
-3.0
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
56
33% active weight
Current posture
7d trendImproving
Δ7d
+4.7
Δ21d
+11.2
Why this grade
Composite grade B. Momentum 83.7 / Value 41.9 / Sentiment 55.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.77B
Beta
-
Shares Out
47.66M
P/E (TTM) · Derived
-17.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-17.19
Rev YoY
-
EPS YoY
-41.1%
Gross Margin
-
Op Margin
-
Net Debt
-$305.28M
Current Ratio
36.37
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology